With an income increase of 30.89% in the first quarter 2026, year on year to cumulative value of $1,837 million, and with 1,147 employees, Exelixis Inc 's income per employee grew on trailing twelve month basis to $ 1,601,241, this marks a new company high for all of 1,147 employees.
The Healthcare sector has seen employees of 4 other companies achieving higher income per employee. While Exelixis Inc 's total ranking has deteriorated compared to the previous quarter from 28 to 129.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

EXEL Net Income per Employee	(Apr 03 2026) I. Quarter	(Jan 02 2026) IV. Quarter	(Oct 03 2025) III. Quarter	(Jul 04 2025) II. Quarter	(Apr 04 2025) I. Quarter
Y / Y Net Income Change	30.89 %	53.16 %	63.53 %	-19.98 %	321.91 %
Net Income per Employee (TTM) $	1,601,242	1,502,856	1,352,392	1,201,335	1,291,743
EXEL's Total Ranking	# 129	# 28	# 71	# 68	# 70
Seq. Net Income Change	-3.83 %	11.49 %	7.4 %	13.68 %	12.53 %

EXEL Company Profile >> Back to EXEL Efficiency Comparisons >> Compare EXEL Net Income per Employee to its Competitors

EXEL Net Income per Employee Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 5
Healthcare Sector	# 19
Overall Market	# 129

Net Income per Employee Statistics
High	Average	Low
$ 1,601,241	$ 326,745	$ -259,646
(Apr 03 2026)		(Jun 30 2014)

Companies with similar Income per Employee for 12 month ending Apr 03 2026, within Healthcare Sector	Income per Employee	Income 12 month ending Apr 03 2026	Number of Employees Apr 03 2026
Aurinia Pharmaceuticals Inc	2,329,789.06	$ 298.213 Million	128
Rigel Pharmaceuticals Inc	2,093,287.36	$ 364.232 Million	174
Quince Therapeutics Inc	2,060,552.63	$ 78.301 Million	38
Zevra Therapeutics Inc	2,036,360.66	$ 124.218 Million	61
Elutia Inc	1,917,076.92	$ 49.844 Million	26
Fortress Biotech Inc	1,653,051.28	$ 128.938 Million	78
Pulmatrix Inc	1,612,500.00	$ 3.225 Million	2
Exelixis Inc	1,601,241.50	$ 1,836.624 Million	1,147
Xoma Royalty Corporation	1,423,714.29	$ 19.932 Million	14
Q32 Bio Inc	1,385,125.00	$ 33.243 Million	24
Petros Pharmaceuticals inc	1,289,601.00	$ 3.869 Million	3
Theravance Biopharma inc	1,272,677.78	$ 114.541 Million	90
Coherus Oncology inc	1,267,115.65	$ 186.266 Million	147
Rafael Holdings Inc	1,224,608.70	$ 28.166 Million	23
Catalyst Pharmaceuticals Inc	1,216,060.44	$ 221.323 Million	182
Tg Therapeutics Inc	1,157,634.09	$ 461.896 Million	399
Glucotrack Inc	1,125,933.33	$ 16.889 Million	15
Ironwood Pharmaceuticals inc	1,021,760.00	$ 102.176 Million	100
Silexion Therapeutics Corp	922,142.86	$ 12.910 Million	14
United Therapeutics Corporation	919,571.43	$ 1,287.400 Million	1,400
Emmis Acquisition Corp	906,895.50	$ 1.814 Million	2
Halozyme Therapeutics Inc	824,687.94	$ 348.843 Million	423

Date modified: 2026-09-08T15:11:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.